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Clinical PerspectiveWhat Is New?Baseline CRP (C‐reactive protein) concentrations might be associated with the benefits of LDL‐C (low‐density lipoprotein cholesterol) lowering on myocardial infarction, but no other outcomes.There appears to be similar risk reductions for more‐ versus less‐intensive LDL‐C--lowering therapy regardless of the magnitude of CRP reduction or the achieved CRP level for all outcomes, but with limited number of trials.What Are the Clinical Implications?More‐intensive LDL‐C lowering appeared to reduce the risk of myocardial infarction (but not other outcomes) to a lesser extent when baseline CRP levels were higher.More‐intensive LDL‐C lowering was associated with similar risk reduction for mortality and other cardiovascular outcomes across baseline CRP concentrations.The achieved and magnitude of reduction in CRP did not seem to have an important association with the benefits of LDL‐C lowering on all outcomes.

Introduction {#jah34330-sec-0008}
============

LDL‐C (Low‐density lipoprotein cholesterol) and inflammation are important risk factors for cardiovascular disease. Lowering LDL‐C with statins or ezetimibe and inhibiting inflammation with canakinumab significantly reduce major cardiovascular events.[1](#jah34330-bib-0001){ref-type="ref"}, [2](#jah34330-bib-0002){ref-type="ref"}, [3](#jah34330-bib-0003){ref-type="ref"}, [4](#jah34330-bib-0004){ref-type="ref"} hsCRP (high‐sensitivity C‐reactive protein) is a predictor of cardiovascular disease and cardiovascular mortality as well as total cholesterol and blood pressure.[5](#jah34330-bib-0005){ref-type="ref"} Several lipid‐lowering therapies (ie, stains and ezetimibe) prove to reduce hsCRP independently of LDL‐C reduction.[6](#jah34330-bib-0006){ref-type="ref"} However, it is inconclusive whether benefits from LDL‐C lowering are associated with baseline CRP concentrations. Larger cardiovascular benefits were observed after statin therapy among patients with elevated baseline CRP concentrations in some trials,[7](#jah34330-bib-0007){ref-type="ref"} but not others.[8](#jah34330-bib-0008){ref-type="ref"}, [9](#jah34330-bib-0009){ref-type="ref"} Similarly, whether achieved and reduction of CRP concentrations would affect benefits from more‐intensive LDL‐C lowering is unknown. We sought to determine whether the benefits of LDL‐C--lowering therapy on cardiovascular events related to baseline, achieved, or magnitude of reduction in CRP concentrations.

Methods {#jah34330-sec-0009}
=======

The data that support the findings of this study are available from Dr Xin‐Lin Zhang upon reasonable request (<xinlzhang0807@gmail.com>). We conducted the meta‐analysis in accord with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guideline.

Data Sources and Searches {#jah34330-sec-0010}
-------------------------

We searched PubMed, EMBASE, and the Cochrane Library from their inception through July 2, 2018. The following keywords were used: lipid lowering, statin, ezetimibe, low‐density lipoprotein cholesterol, randomized controlled trial, and individual drug names of statins. The search strategy is provided in Data [S1](#jah34330-sup-0001){ref-type="supplementary-material"}. One reviewer (X.Z.) identified potential relevant citations from reference lists of the identified reports and relevant reviews.

Study Selection {#jah34330-sec-0011}
---------------

Two reviewers (X.Z. and R.L.) independently evaluated the eligibility of studies. Discrepancies were resolved by discussion (W.X.). The main inclusion criteria were: (1) randomized controlled cardiovascular outcome trials involving human subjects; (2) evaluated any comparison of the following strategies: statins, ezetimibe, or placebo (therapy to lower LDL‐C versus no therapy or more‐ versus less‐intensive intervention); and (3) included a minimum of 500 patients and 40 clinical events and reported outcomes of interest with at least 6 months of follow‐up. We excluded trials investigating LDL‐C--lowering drugs other than statins and ezetimibe. Trials with PCSk9 (proprotein convertase subtilisin/kexin type 9) monoclonal antibodies were excluded because they do not affect CRP concentrations. We did not impose limitations on language, sex, or age.

Outcomes of Interest {#jah34330-sec-0012}
--------------------

Outcomes of interest were all‐cause and cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, and major adverse cardiovascular events (MACEs).

Data Extraction and Assessment of Study Quality {#jah34330-sec-0013}
-----------------------------------------------

Three investigators (X.Z., R.L., and W.X.) independently extracted data using a prespecified form. Median CRP and mean LDL‐C values were abstracted from each trial. Two reviewers (X.Z and W.X.) independently assessed risk of bias of each trial by using the Cochrane Collaboration\'s tool,[10](#jah34330-bib-0010){ref-type="ref"} which assessing random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias. Consensus was achieved through referral to a third investigator (L.W.) in case of disagreement.

Data Synthesis and Statistical Analysis {#jah34330-sec-0014}
---------------------------------------

To investigate the association between baseline CRP concentrations and risks of mortality and cardiovascular outcomes with more‐intensive LDL‐C lowering, random‐effects meta‐regression analysis was performed, with log‐transformed baseline CRP concentration as the covariate for the main model. Several other variables were added in the adjusted analyses, which included age, absolute magnitude of reduction in CRP concentrations (difference between achieved CRP concentrations in the more‐ and less‐intensive study arms), baseline LDL‐C, and absolute magnitude of reduction in LDL‐C concentrations. Baseline CRP concentrations were log‐transformed because their distributions were markedly skewed. Similar analyses were carried out for achieved and magnitude of reduction in CRP concentrations. Given that statins and ezetimibe differ in their effects on CRP concentrations, we performed sensitivity analyses restricted to statin trials. We also performed sensitivity analyses based on different study populations (primary or secondary prevention trials). To account for the variability in the length of follow‐up for each of these trials, we used rate ratios (RRs) with their corresponding 95% CIs adjusted for patient‐years as the statistic estimate.

Prespecified subgroup analyses were performed for all outcomes (see Data [S1](#jah34330-sup-0001){ref-type="supplementary-material"}). A test for subgroup differences was performed across the examined subgroups with a χ^2^ test of interaction. Heterogeneity was assessed by the Cochran Q test and the I^2^ statistic. We examined potential publication bias by visually inspecting the asymmetry of the funnel plot and Begg\'s test. For the summary treatment effect estimate, a 2‐tailed *P* value \<0.05 was considered statistically significant. Analyses were conducted with Stata software (version 12.0; StataCorp LP, College Station, TX) and Review Manager (version 5.3; Cochrane Collaboration).

Results {#jah34330-sec-0015}
=======

Study Selection and Characteristics {#jah34330-sec-0016}
-----------------------------------

The flow diagram of the study selection is shown in Figure [S1](#jah34330-sup-0001){ref-type="supplementary-material"}. Twenty‐four trials were included in the meta‐analysis and metaregression analysis.[3](#jah34330-bib-0003){ref-type="ref"}, [11](#jah34330-bib-0011){ref-type="ref"}, [12](#jah34330-bib-0012){ref-type="ref"}, [13](#jah34330-bib-0013){ref-type="ref"}, [14](#jah34330-bib-0014){ref-type="ref"}, [15](#jah34330-bib-0015){ref-type="ref"}, [16](#jah34330-bib-0016){ref-type="ref"}, [17](#jah34330-bib-0017){ref-type="ref"}, [18](#jah34330-bib-0018){ref-type="ref"}, [19](#jah34330-bib-0019){ref-type="ref"}, [20](#jah34330-bib-0020){ref-type="ref"}, [21](#jah34330-bib-0021){ref-type="ref"}, [22](#jah34330-bib-0022){ref-type="ref"}, [23](#jah34330-bib-0023){ref-type="ref"}, [24](#jah34330-bib-0024){ref-type="ref"}, [25](#jah34330-bib-0025){ref-type="ref"}, [26](#jah34330-bib-0026){ref-type="ref"}, [27](#jah34330-bib-0027){ref-type="ref"}, [28](#jah34330-bib-0028){ref-type="ref"}, [29](#jah34330-bib-0029){ref-type="ref"}, [30](#jah34330-bib-0030){ref-type="ref"}, [31](#jah34330-bib-0031){ref-type="ref"}, [32](#jah34330-bib-0032){ref-type="ref"}, [33](#jah34330-bib-0033){ref-type="ref"} Twelve trials that were otherwise eligible were not included because CRP concentrations were not reported. All trials except 1 were multicenter studies. Statin monotherapy was used in 20 trials and statin and ezetimibe in 4 trials. Overall, 171 250 patients were randomly assigned to more‐ or less‐intensive LDL‐C--lowering treatments. Median follow‐up duration was 4.2 years (range, 1--11.5). Mean age of patients were 62.7 years, and 73.0% were men. The median baseline CRP concentration was 3.1 mg/L and ranged from 0.57 to 21.2 mg/L. Detailed characteristics of each trial are presented in Tables [S1](#jah34330-sup-0001){ref-type="supplementary-material"} through [S3](#jah34330-sup-0001){ref-type="supplementary-material"}.

Risk of Bias in the Included Trials {#jah34330-sec-0017}
-----------------------------------

Risk of bias for each trial is shown in Table [S4](#jah34330-sup-0001){ref-type="supplementary-material"}. Most trials had blinded outcome adjudication and blinding of participants and personnel. Risk for attrition bias and reporting bias were generally low. Publication bias was detected for a number of outcomes, as revealed by visual inspection of the funnel plots and Begg\'s test (Figure [S2](#jah34330-sup-0001){ref-type="supplementary-material"}).

All‐Cause Mortality {#jah34330-sec-0018}
-------------------

There were 8355 deaths among 83 209 patients randomly assigned to receive more‐intensive LDL‐C--lowering treatment and 8989 deaths among 83 018 patients assigned to less‐intensive LDL‐C--lowering treatment. Metaregression analysis showed that all‐cause mortality risk was not significantly different for each 1‐mg/L higher log‐transformed baseline CRP concentration between more‐ versus less‐intensive LDL‐C--lowering treatments (RR, 0.98; 95% CI, 0.91--1.05; *P*=0.512; Figure [1](#jah34330-fig-0001){ref-type="fig"}), with or without multivariable adjustment ([Table](#jah34330-tbl-0001){ref-type="table"}). A similar observation was found for magnitude of reduction in CRP concentrations (RR, 0.98; 95% CI, 0.91--1.06; *P*=0.590; Figure [S3](#jah34330-sup-0001){ref-type="supplementary-material"}). The overall risk reduction in all‐cause mortality with more‐ versus less‐intensive therapy across all trials was 0.91 (95% CI, 0.87--0.96) and were consistent across the range of baseline (Figure [2](#jah34330-fig-0002){ref-type="fig"}) and magnitude of reduction in CRP concentrations (Figure [S4](#jah34330-sup-0001){ref-type="supplementary-material"}).

![Meta‐regression analysis of all‐cause mortality rate ratios plotted against log‐transformed baseline CRP concentrations in the more‐intensive group. The size of the data marker is proportional to the weight in the metaregression. CRP indicates C‐reactive protein; RR, rate ratio.](JAH3-8-e012428-g001){#jah34330-fig-0001}

###### 

Multivariable Metaregression Models for the Association of Each 1‐mg/L Increase in log(Baseline CRP Concentration), Magnitude of Reduction in CRP Concentration, Achieved CRP, and Mortality and Cardiovascular Outcomes

  Outcomes                     No. of Trials   log(Baseline CRP)   Rate Ratio (95% CI)                                           
  ---------------------------- --------------- ------------------- --------------------- ------------------- ------------------- -------------------
  All‐cause mortality          22              0.98 (0.91, 1.05)   1.00 (0.92, 1.10)     1.01 (0.90, 1.13)   0.98 (0.91, 1.06)   1.00 (0.96, 1.03)
  Cardiovascular mortality     22              1.01 (0.91, 1.12)   1.02 (0.89, 1.16)     1.03 (0.89, 1.19)   0.97 (0.87, 1.08)   1.00 (0.94, 1.05)
  Myocardial infarction        24              1.12 (1.04, 1.22)   1.16 (1.05, 1.27)     1.16 (1.02, 1.33)   0.93 (0.84, 1.04)   0.98 (0.93, 1.04)
  Stroke                       24              0.94 (0.84, 1.05)   0.96 (0.84, 1.09)     0.96 (0.81, 1.13)   0.90 (0.80, 1.01)   0.97 (0.91, 1.03)
  Coronary revascularization   22              1.06 (1.00, 1.13)   1.07 (0.99, 1.15)     1.05 (0.96, 1.14)   0.94 (0.84, 1.04)   0.99 (0.94, 1.04)
  MACE                         24              1.04 (0.98, 1.11)   1.05 (0.96, 1.15)     1.08 (0.97, 1.19)   0.96 (0.89, 1.03)   0.99 (0.95, 1.03)

CRP indicates C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; MACE, major adverse cardiovascular event.

![Meta‐analysis of all‐cause mortality stratified by baseline CRP concentrations between more‐ and less‐intensive lipid‐lowering group. CRP indicates C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol.](JAH3-8-e012428-g002){#jah34330-fig-0002}

Cardiovascular Mortality {#jah34330-sec-0019}
------------------------

Metaregression analysis showed that cardiovascular mortality risk was not significantly different for each 1‐mg/L higher log‐transformed baseline CRP concentration between more‐ versus less‐intensive LDL‐C--lowering treatments (RR, 1.01; 95% CI, 0.91--1.12; *P*=0.803; Figure [3](#jah34330-fig-0003){ref-type="fig"}), with or without multivariable adjustment ([Table](#jah34330-tbl-0001){ref-type="table"}). A similar observation was found for magnitude of reduction in CRP concentrations (RR, 0.97; 95% CI, 0.87--1.08; *P*=0.542; Figure [S5](#jah34330-sup-0001){ref-type="supplementary-material"}). The overall risk reduction in cardiovascular mortality with more‐ versus less‐intensive therapy across all trials was 0.84 (95% CI, 0.79--0.90) and was consistent across the range of baseline (Figure [4](#jah34330-fig-0004){ref-type="fig"}) and magnitude of reduction in CRP concentrations (Figure [S6](#jah34330-sup-0001){ref-type="supplementary-material"}).

![Meta‐regression analysis of cardiovascular mortality rate ratios plotted against log‐transformed baseline CRP concentrations in the more‐intensive group. The size of the data marker is proportional to the weight in the metaregression. CRP indicates C‐reactive protein; RR, rate ratio.](JAH3-8-e012428-g003){#jah34330-fig-0003}

![Meta‐analysis of cardiovascular mortality stratified by baseline CRP concentrations between more‐ and less‐intensive lipid‐lowering group. CRP indicates C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol.](JAH3-8-e012428-g004){#jah34330-fig-0004}

Myocardial Infarction {#jah34330-sec-0020}
---------------------

Overall, 3745 of 85 723 patients receiving the more‐intensive LDL‐C--lowering strategy versus 4825 of 85 527 receiving the less‐intensive strategy experienced myocardial infarction. Metaregression showed that more‐ versus less‐intensive LDL‐C lowering was associated with a significant change in RR for myocardial infarction (RR, 1.12; 95% CI, 1.04--1.22; *P*=0.007) for each 1‐mg/L higher log‐transformed baseline CRP concentration (Figure [5](#jah34330-fig-0005){ref-type="fig"}), with or without multivariable adjustment ([Table](#jah34330-tbl-0001){ref-type="table"}). The overall risk reduction in myocardial infarction associated with more‐ versus less‐intensive therapy across all trials was 0.75 (95% CI, 0.70--0.81), but varied by baseline CRP concentration (Figure [6](#jah34330-fig-0006){ref-type="fig"}). The RR was 0.79 (95% CI, 0.72--0.87) in trials with baseline CRP concentrations ≥2.7 mg/L (median) and 0.70 (95% CI, 0.65--0.76) in trials with baseline CRP concentrations \<2.7 mg/L (*P*=0.060 for interaction). Metaregression analysis did not show a significant correlation between magnitude of reduction in CRP concentrations and risk of myocardial infarction (RR, 0.93; 95% CI, 0.84--1.04; *P*=0.19; Figure [S7](#jah34330-sup-0001){ref-type="supplementary-material"}). The overall risk reduction in myocardial infarction with more‐ versus less‐intensive therapy was consistent across the range of magnitude of reduction in CRP concentrations (Figure [S8](#jah34330-sup-0001){ref-type="supplementary-material"}).

![Meta‐regression analysis of myocardial infarction rate ratios plotted against log‐transformed baseline CRP concentrations in the more‐intensive group. The size of the data marker is proportional to the weight in the metaregression. CRP indicates C‐reactive protein; RR, rate ratio.](JAH3-8-e012428-g005){#jah34330-fig-0005}

![Meta‐analysis of myocardial infarction stratified by baseline CRP concentrations between more‐ and less‐intensive lipid‐lowering group. CRP indicates C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol.](JAH3-8-e012428-g006){#jah34330-fig-0006}

Stroke {#jah34330-sec-0021}
------

Metaregression analysis showed that stroke risk was not significantly different for each 1‐mg/L higher log‐transformed baseline CRP concentration between more‐ versus less‐intensive LDL‐C--lowering treatments (RR, 0.94; 95% CI, 0.84--1.05; *P*=0.253; Figure [S9](#jah34330-sup-0001){ref-type="supplementary-material"}), with or without multivariable adjustment ([Table](#jah34330-tbl-0001){ref-type="table"}). A similar observation was found for magnitude of reduction in CRP concentrations (RR, 0.90; 95% CI, 0.80--1.01; *P*=0.084; Figure [S10](#jah34330-sup-0001){ref-type="supplementary-material"}). The overall risk reduction in stroke with more‐ versus less‐intensive therapy across all trials was consistent across the range of baseline (Figure [S11](#jah34330-sup-0001){ref-type="supplementary-material"}) and magnitude of reduction in CRP concentrations (Figure [S12](#jah34330-sup-0001){ref-type="supplementary-material"}).

Coronary Revascularization {#jah34330-sec-0022}
--------------------------

For each 1‐mg/L higher log‐transformed baseline CRP concentration, more‐ versus less‐intensive LDL‐C lowering was associated with a modest change in RRs for coronary revascularization (RR, 1.06; 95% CI, 1.00--1.13; *P*=0.062; Figure [S13](#jah34330-sup-0001){ref-type="supplementary-material"}), which became nonsignificant after multivariable adjustment ([Table](#jah34330-tbl-0001){ref-type="table"}). Metaregression analysis did not show a significant correlation between magnitude of reduction in CRP concentrations and risk of revascularization (RR, 0.94; 95% CI, 0.84--1.04; *P*=0.181; Figure [S14](#jah34330-sup-0001){ref-type="supplementary-material"}). The overall risk reduction in coronary revascularization with more‐ versus less‐intensive therapy across all trials was consistent across the range of baseline (Figure [S15](#jah34330-sup-0001){ref-type="supplementary-material"}) and magnitude of reduction in CRP concentrations (Figure [S16](#jah34330-sup-0001){ref-type="supplementary-material"}).

Major Adverse Cardiovascular Events {#jah34330-sec-0023}
-----------------------------------

Metaregression analysis showed that MACE risk was not significantly different for each 1‐mg/L higher log‐transformed baseline CRP concentration between more‐ versus less‐intensive LDL‐C--lowering treatments (RR, 1.04; 95% CI, 0.98--1.11; *P*=0.182; Figure [S17](#jah34330-sup-0001){ref-type="supplementary-material"}), with or without multivariable adjustment ([Table](#jah34330-tbl-0001){ref-type="table"}). A similar observation was found for magnitude of reduction in CRP concentrations (RR, 0.96; 95% CI, 0.89--1.03; *P*=0.252; Figure [S18](#jah34330-sup-0001){ref-type="supplementary-material"}). The overall risk reduction in MACE with more‐ versus less‐intensive therapy across all trials was consistent across the range of baseline (Figure [S19](#jah34330-sup-0001){ref-type="supplementary-material"}) and magnitude of reduction in CRP concentrations (Figure [S20](#jah34330-sup-0001){ref-type="supplementary-material"}).

Additional Analyses {#jah34330-sec-0024}
-------------------

Analyses excluding trials with heart failure or chronic kidney disease requiring hemodialysis, trials with less than 1000 patients, or trials published before 2000 yielded similar results (Table [S5](#jah34330-sup-0001){ref-type="supplementary-material"}), as were analyses stratified by types of intervention in the more‐intensive LDL‐C--lowering treatment (Table [S6](#jah34330-sup-0001){ref-type="supplementary-material"}), types of treatment in the less‐intensive LDL‐C--lowering treatment (Table [S7](#jah34330-sup-0001){ref-type="supplementary-material"}), and type of population (Table [S8](#jah34330-sup-0001){ref-type="supplementary-material"}). Consistent with previous studies, a lack of significant reduction in all‐cause and cardiovascular mortality was observed in statin with ezetimibe trials (Table [S6](#jah34330-sup-0001){ref-type="supplementary-material"}).

Metaregression analysis restricted to statin trials confirmed that more‐ versus less‐intensive LDL‐C lowering was associated with a significant change in RRs for myocardial infarction, but no other outcomes of interest (Table [S9](#jah34330-sup-0001){ref-type="supplementary-material"}). For each 1‐mg/L higher log‐transformed baseline CRP concentration, more‐ versus less‐intensive LDL‐C lowering was associated with a significant change in RRs for myocardial infarction (RR, 1.12; 95% CI, 1.03--1.21; *P*=0.011) in secondary prevention trials (Table [S10](#jah34330-sup-0001){ref-type="supplementary-material"}; Figure [S21](#jah34330-sup-0001){ref-type="supplementary-material"}), but not in primary prevention trials (Table [S11](#jah34330-sup-0001){ref-type="supplementary-material"}). Metaregression and meta‐analysis of mortality and cardiovascular outcomes found no association with achieved CRP concentrations ([Table](#jah34330-tbl-0001){ref-type="table"}; Figures [S22](#jah34330-sup-0001){ref-type="supplementary-material"} through [S27](#jah34330-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah34330-sec-0025}
==========

In this meta‐analysis and metaregression analysis of 24 trials involving \>170 000 patients and ≈24 000 clinical events, more‐intensive LDL‐C lowering appeared to reduce the risk of myocardial infarction to a lesser extent when baseline CRP levels were higher, but was associated with similar risk reduction for mortality and other cardiovascular outcomes across baseline CRP concentrations. Similar risk reductions occurred for more‐ versus less‐intensive LDL‐C--lowering therapy regardless of the magnitude of CRP reduction or the achieved CRP level for all outcomes.

Plasma CRP concentrations is a predictor of cardiovascular risk independent of other risk factors.[1](#jah34330-bib-0001){ref-type="ref"} Although a causal role of CRP for atherosclerosis and ischemic vascular disease is not supported by previous studies,[34](#jah34330-bib-0034){ref-type="ref"} there is potential in using CRP concentration as a marker for benefit from LDL‐C--lowering therapy. In the AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention) trial, patients with an elevated baseline CRP concentration benefited markedly from lovastatin, whereas those with a low baseline CRP level had no cardiovascular benefit.[7](#jah34330-bib-0007){ref-type="ref"} However, others have not shown such an association both in primary and secondary prevention trials.[8](#jah34330-bib-0008){ref-type="ref"} Our present metaregression analyses demonstrated no association between baseline CRP concentrations with mortality outcomes following LDL‐C lowering, which, to the best of our knowledge, has not been evaluated in randomized trials because of the rarity of mortality outcomes. It is worth noting that a significant association between baseline CRP concentrations and risks for myocardial infarction was evident, with a less‐robust benefit for more‐intensive LDL‐C lowering in patients who had higher baseline CRP concentrations. In line with our finding, post‐hoc analyses of the JUPITER (the JUPITER trial from the US Food and Drug Administration) trial from the US Food and Drug Administration revealed an inverse relationship between baseline hsCRP concentrations and clinical response to statin therapy.[35](#jah34330-bib-0035){ref-type="ref"} Subjects with baseline hsCRP above the median cut point of 4.2 mg/L had lower relative risk reduction with statin therapy than those with hsCRP \<4.2 mg/L (relative risk reduction, 29% versus 58%).[35](#jah34330-bib-0035){ref-type="ref"} The very recently published St. Francis Heart Study also reported a trend toward less benefit in patients with higher baseline hsCRP.[36](#jah34330-bib-0036){ref-type="ref"}

Several trials suggest that achieving lower CRP concentrations might be associated with better outcomes for patients being treated with statins.[37](#jah34330-bib-0037){ref-type="ref"}, [38](#jah34330-bib-0038){ref-type="ref"}, [39](#jah34330-bib-0039){ref-type="ref"}, [40](#jah34330-bib-0040){ref-type="ref"}, [41](#jah34330-bib-0041){ref-type="ref"} In the PROVE IT‐TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy--Thrombolysis In Myocardial Infarction 22) trial, patients who achieved CRP concentrations of \<2 mg/L after statin therapy had a lower rate of cardiovascular events than those who did not.[38](#jah34330-bib-0038){ref-type="ref"} A similarly negative association was detected in the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering),[39](#jah34330-bib-0039){ref-type="ref"} A‐to‐Z (Aggrastat‐to‐Zocor),[40](#jah34330-bib-0040){ref-type="ref"} and the JUPITER[41](#jah34330-bib-0041){ref-type="ref"} trials. Fueling this debate, trials including the ASCOT‐LLA (Anglo‐Scandinavian Cardiac Outcome Trial--Lipid Lowering Arm),[42](#jah34330-bib-0042){ref-type="ref"} the CARDS (Collaborative Atorvastatin Diabetes Study),[43](#jah34330-bib-0043){ref-type="ref"} and TNT (Treating New Targets)[44](#jah34330-bib-0044){ref-type="ref"} studies showed no association between achieved hsCRP concentrations and magnitude of statin efficacy in the prevention of cardiovascular events. Our meta‐analysis and metaregression analysis do not lend support to the hypotheses that the beneficial effects of LDL‐C--lowering therapy are affected by achieved CRP concentrations, in contrast with those found with achieved LDL‐C concentrations.[45](#jah34330-bib-0045){ref-type="ref"}, [46](#jah34330-bib-0046){ref-type="ref"}

The REVERSAL trial demonstrates that magnitude of reduction in CRP concentrations is significantly correlated with rate of progression of atherosclerosis (determined with intravascular ultrasonography).[39](#jah34330-bib-0039){ref-type="ref"} The JUPITER trial also shows an association with magnitude of cardiovascular benefit of statin therapy.[41](#jah34330-bib-0041){ref-type="ref"} However, evidence remains scare given that the vast majority of trials did not report these relationship data. Our metaregression analysis revealed no significant correlation between magnitude of reduction in CRP concentrations and benefit from LDL‐C--lowering therapy, which needs to be confirmed in large, prospective trials in the future.

Although previous LDL‐C--lowering trials with stains or ezetimibe reduce CRP concentrations, the concomitant reduction of LDL‐C makes it difficult to conclude a causal role of inflammation in atherothrombotic events. The recently published CANTOS (Canakinumab Anti‐inflammatory Thrombosis Outcomes Study) trial, which enrolled 10 061 patients with previous myocardial infarction and an hsCRP level of ≥2 mg/L, is a proof‐of‐concept trial directly testing the inflammatory hypothesis of atherothrombosis.[4](#jah34330-bib-0004){ref-type="ref"} Canakinumab confers a significant 15% reduction in MACEs without altering the lipid profile, supporting that reducing inflammation per se could reduce vascular risk.[4](#jah34330-bib-0004){ref-type="ref"} Of note, a CRP concentration \<2 mg/dL after the first dose of cankinumab was associated with greater relative reduction in MACE risk.[47](#jah34330-bib-0047){ref-type="ref"} Canakinumab\'s reduction in atherothrombotic events involves inhibition of interleukin‐6, indicating that treatments targeting downstream from interleukin‐1β merit evaluation for cardiovascular benefits.[48](#jah34330-bib-0048){ref-type="ref"} However, whether the cardiovascular benefits of canakinumab will translate to other targeted anti‐inflammatory treatments that reduce CRP remains to be determined. If confirmed, whether these benefits relate to baseline, achieved, or reduction of CRP concentrations also requires investigation.

Limitations {#jah34330-sec-0026}
===========

Our study has several limitations. First, our analysis was based on trial‐level data rather than patient‐level data. Metaregression analyses might be subject to risk of aggregation bias because they attempt to make inferences about individuals using study‐level information.[49](#jah34330-bib-0049){ref-type="ref"} Second, a number of LDL‐C--lowering cardiovascular trials did not report CRP data (especially achieved CRP concentrations), which might contribute to the publication bias detected in several analyses. The inclusion of these trials, if CRP data are reported, might erase the publication bias and considerably improve the statistical power and improve strength of evidence of our analysis. Third, considerable heterogeneity was detected in several analyses, which may be attributed to the differences in patient characteristics not evaluated in our study given that no characteristics tested appeared to affect the results. Fourth, the inclusion criteria in these trials varied; these differences in selection will play out in the baseline risk and the magnitude of absolute risk reduction achieved. Fifth, the definitions of some outcomes, such as MACE and myocardial infarction, were not completely consistent across trials, and a considerable part of trials did not report outcome definition; it is unclear whether this variation could affect our results. Finally, the study enrollment included in the analysis extended from 1995 to 2018, during which background therapy and cardiovascular event rates have changed.

Conclusions {#jah34330-sec-0027}
===========

In this metaregression and meta‐analysis, more‐intensive LDL‐C lowering might have reduced the risk of myocardial infarction to a lesser extent when baseline CRP levels were higher, but was associated with similar risk reduction for mortality and other cardiovascular outcomes across baseline CRP concentrations. Similar risk reductions occurred for more‐ versus less‐intensive LDL‐C--lowering therapy regardless of the magnitude of CRP reduction or the achieved CRP level for all outcomes.

Sources of Funding {#jah34330-sec-0028}
==================

This study was supported by the National Natural Science Foundation of China (No. 81600312) and Fund for Distinguished Young Scholars of Nanjing (JQX15002). The funders had no role in the study design, data collection and analysis, writing of the report, and decision to submit the article for publication.

Disclosures {#jah34330-sec-0029}
===========

None.

Supporting information
======================

###### 

**Data S1.** Supplemental methods.

**Table S1.** Study and Patient Baseline Characteristics

**Table S2.** Study Characteristics of the Included Randomized Trials

**Table S3.** Inclusion and Exclusion criteria of Included Randomized Controlled Trials

**Table S4.** Listing of Potential Sources of Bias

**Table S5.** Meta‐Analysis Excluding Trials With Potential Bias

**Table S6.** Sensitivity Analysis Stratified for Agent Used in the More‐Intensive Treatment Group

**Table S7.** Sensitivity Analysis Stratified for the Type of Treatment in the Less‐Intensive Group

**Table S8.** Sensitivity Analysis Stratified for the Type of Population

**Table S9.** Multivariable Metaregression Models for the Association of Each 1‐mg/L Reduction in log(baseline CRP Concentration), Magnitude of Reduction in CRP Concentration, and Mortality and Cardiovascular Outcomes in Statin Trials

Table S10. Multivariable Metaregression Models for the Association of Each 1‐mg/L Reduction in log(baseline CRP Concentration), Magnitude of Reduction in CRP Concentration, and Mortality and Cardiovascular Outcomes in Secondary Prevention Trials\*
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**Figure S1.** Identification and selection of randomized clinical trials evaluating the effect of low‐density lipoprotein cholesterol--lowering therapy on cardiovascular outcomes.

**Figure S2.** Publication bias. (A) All‐cause mortality; (B) cardiovascular mortality; (C) myocardial infarction; (D) stroke; (E) coronary revascularization; and (F) MACE.

**Figure S3.** Metaregression analysis of all‐cause mortality rate ratio plotted against magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S4.** Meta‐analysis of all‐cause mortality stratified by magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S5.** Metaregression analysis of cardiovascular mortality rate ratio plotted against magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S6**. Meta‐analysis of cardiovascular mortality stratified by magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S7**. Metaregression analysis of myocardial infarction rate ratio plotted against magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S8.** Meta‐analysis of myocardial infarction stratified by magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S9.** Metaregression analysis of stroke rate ratio plotted against log(baseline CRP concentrations) in the more‐intensive group.

**Figure S10.** Metaregression analysis of stroke‐rate ratio plotted against magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S11.** Meta‐analysis of stroke stratified by baseline CRP concentrations.

**Figure S12.** Meta‐analysis of stroke stratified by magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S13.** Metaregression analysis of coronary revascularization‐rate ratio plotted against log(baseline CRP concentrations) in the more‐intensive group.

**Figure S14.** Metaregression analysis of coronary revascularization‐rate ratio plotted against magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S15.** Meta‐analysis of coronary revascularization stratified by baseline CRP concentrations.

**Figure S16.** Meta‐analysis of coronary revascularization stratified by magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S17.** Metaregression analysis of mace rate ratio plotted against log(baseline CRP concentrations) in the more‐intensive group.

**Figure S18.** Metaregression analysis of MACE‐rate ratio plotted against magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S19.** Meta‐analysis of MACE stratified by baseline CRP concentrations.

**Figure S20.** Meta‐analysis of MACE stratified by magnitude of reduction in CRP concentrations between more‐ and less‐intensive lipid‐lowering group.

**Figure S21.** Metaregression analysis of myocardial‐infarction--rate ratio plotted against log(baseline CRP concentrations) in the secondary prevention trials.

**Figure S22.** Meta‐analysis of all‐cause mortality stratified by the achieved CRP concentrations.

**Figure S23.** Meta‐analysis of cardiovascular mortality stratified by the achieved CRP concentrations.

**Figure S24.** Meta‐analysis of myocardial infarction stratified by the achieved CRP concentrations.

**Figure S25.** Meta‐analysis of stroke stratified by the achieved CRP concentrations.

**Figure S26.** Meta‐analysis of coronary revascularization stratified by the achieved CRP concentrations.

**Figure S27.** Meta‐analysis of MACE stratified by the achieved CRP concentrations.
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